Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial.
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
This study examined the role of dopaminergic genes in prospective smoking cessation and response to bupropion treatment in a placebo-controlled clinical trial. Smokers of European ancestry (N=418) provided blood samples for genetic analysis and received either bupropion or placebo (10 weeks) plus counseling. Assessments included the dopamine D2 receptor (DRD2) genotype, dopamine transporter (SLC6A3) genotype, demographic factors, and nicotine dependence. Smoking status was verified at the end of treatment (EOT) and at 6-month follow-up. The results provided evidence for a significant DRD2 * SLC6A3 interaction effect on prolonged smoking abstinence and time to relapse at EOT, independent of treatment condition. Such effects were no longer significant at 6-month follow-up, however. These results provide the first evidence from a prospective clinical trial that genes that alter dopamine function may influence smoking cessation and relapse during the treatment phase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Predictive reward signal of dopamine neurons
Schultz, W. (1998) · Journal of Neurophysiology · doi:10.1152/jn.1998.80.1.1 · Cited by 4,564
Biochemical verification of tobacco use and cessation
Benowitz, N. L., III, P. J., Ahijevych, K., Jarvis, M. J., Hall, S., LeHouezec, J., Hansson, A., Lichtenstein, E., Henningfield, J., Tsoh, J., et al. (2002) · Nicotine & Tobacco Research · doi:10.1080/14622200210123581 · Cited by 1,800
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 1×
“Six-month abstinence rates for smokers treated with bupropion are reported to be 25%–35%, as compared with 15%–20% for placebo (Hurt et al., 1997; Jorenby et al., 1999).”
MethodEffects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
Noble, E. P. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810310066012 · Cited by 655
Thompson, J., Thomas, N., Singleton, A., Piggot, M., Lloyd, S., Perry, E. K., Morris, C. M., Perry, R. H., Ferrier, I. N., & Court, J. A. (1997) · Pharmacogenetics · doi:10.1097/00008571-199712000-00006 · Cited by 553
Genotype Influences In Vivo Dopamine Transporter Availability in Human Striatum
Heinz, A. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00099-8 · Cited by 538 · cited 1×
“Nicotine dependence. The Fagerstrom Test for Nicotine Dependence (FTND) is a 6-item self-report measure of nicotine dependence derived from the Fagerstrom Tolerance Questionnaire ( Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991 ).”
MethodBupropion is a nicotinic antagonist
Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38905-0 · Cited by 509
Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation
Silagy, C., Mant, D., Fowler, G., & Lodge, M. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90933-4 · Cited by 481
Cited by
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub3 · Cited by 567
Relapse prevention for addictive behaviors
Hendershot, C. S., Witkiewitz, K., George, W. H., & Marlatt, G. A. (2011) · Substance Abuse Treatment, Prevention, and Policy · doi:10.1186/1747-597x-6-17 · Cited by 467
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Piasecki, T. M. (2006) · Clinical Psychology Review · doi:10.1016/j.cpr.2005.11.007 · Cited by 370
Bupropion: pharmacology and therapeutic applications
Foley, K. F., DeSanty, K. P., & Kast, R. E. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.9.1249 · Cited by 352
Metadata
- Authors
- Lerman, C., Shields, P. G., Wileyto, E. P., Audrain, J., Hawk, L. H., Pinto, A., Kucharski, S., Krishnan, S., Niaura, R., & Epstein, L. H.
- Venue
- Health Psychology
- Published
- 2003
- Volume
- 22
- Issue
- 5
- Pages
- 541-548
- ISSN
- 0278-6133 (ISSN-L)
- 1930-7810
- OpenAlex
- W2030965982
- Cited by
- 155
- References
- 15
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. https://app.cochat.ai/papers/10.1037/0278-6133.22.5.541
- The paper
- Lerman, C., Shields, P. G., Wileyto, E. P., Audrain, J., Hawk, L. H., Pinto, A., Kucharski, S., Krishnan, S., Niaura, R., & Epstein, L. H. (2003). Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychology. https://doi.org/10.1037/0278-6133.22.5.541
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.